Lower extremity arterial disease
Lower Limbs Arterial Disease (LEAD) affects over 40 million people in Europe and appears to be 2-4 times more prevalent in people with type 2 diabetes (PWT2D) than in the general population. LEAD patients need intensive prevention and management of risk factors. Cigarette smoking is one of the most...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Series: | Vascular Investigation and Therapy |
| Subjects: | |
| Online Access: | http://www.vitonline.org/article.asp?issn=2589-9686;year=2023;volume=6;issue=4;spage=87;epage=92;aulast=Antignani |
| _version_ | 1797246060379242496 |
|---|---|
| author | Pier Luigi Antignani |
| author_facet | Pier Luigi Antignani |
| author_sort | Pier Luigi Antignani |
| collection | DOAJ |
| description | Lower Limbs Arterial Disease (LEAD) affects over 40 million people in Europe and appears to be 2-4 times more prevalent in people with type 2 diabetes (PWT2D) than in the general population. LEAD patients need intensive prevention and management of risk factors. Cigarette smoking is one of the most important risk factors for peripheral arterial disease as well as hyperlipoproteinemia and hypertension. Diabetic metabolic disorders are the most important risk factors for LEAD progression. The antiplatelet drugs represent one of the basic options for the management of patients with various atherosclerotic diseases. Aspirin is the oldest and most often prescribed antiplatelet drug. Lifestyle management remains the cornerstones of LEAD patients management. |
| first_indexed | 2024-04-24T19:36:48Z |
| format | Article |
| id | doaj.art-bcc47b2f1d5640c0829ad1691c3d62c8 |
| institution | Directory Open Access Journal |
| issn | 2589-9686 2589-9481 |
| language | English |
| last_indexed | 2024-04-24T19:36:48Z |
| publishDate | 2023-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Vascular Investigation and Therapy |
| spelling | doaj.art-bcc47b2f1d5640c0829ad1691c3d62c82024-03-25T13:07:59ZengWolters Kluwer Medknow PublicationsVascular Investigation and Therapy2589-96862589-94812023-01-0164879210.4103/VIT.VIT_17_24Lower extremity arterial diseasePier Luigi AntignaniLower Limbs Arterial Disease (LEAD) affects over 40 million people in Europe and appears to be 2-4 times more prevalent in people with type 2 diabetes (PWT2D) than in the general population. LEAD patients need intensive prevention and management of risk factors. Cigarette smoking is one of the most important risk factors for peripheral arterial disease as well as hyperlipoproteinemia and hypertension. Diabetic metabolic disorders are the most important risk factors for LEAD progression. The antiplatelet drugs represent one of the basic options for the management of patients with various atherosclerotic diseases. Aspirin is the oldest and most often prescribed antiplatelet drug. Lifestyle management remains the cornerstones of LEAD patients management.http://www.vitonline.org/article.asp?issn=2589-9686;year=2023;volume=6;issue=4;spage=87;epage=92;aulast=Antignaniatherosclerosisclaudicationdiabeteslower limbs arterial disease |
| spellingShingle | Pier Luigi Antignani Lower extremity arterial disease Vascular Investigation and Therapy atherosclerosis claudication diabetes lower limbs arterial disease |
| title | Lower extremity arterial disease |
| title_full | Lower extremity arterial disease |
| title_fullStr | Lower extremity arterial disease |
| title_full_unstemmed | Lower extremity arterial disease |
| title_short | Lower extremity arterial disease |
| title_sort | lower extremity arterial disease |
| topic | atherosclerosis claudication diabetes lower limbs arterial disease |
| url | http://www.vitonline.org/article.asp?issn=2589-9686;year=2023;volume=6;issue=4;spage=87;epage=92;aulast=Antignani |
| work_keys_str_mv | AT pierluigiantignani lowerextremityarterialdisease |